2008 French national guidelines for the treatment of venous thromboembolism in patients with cancer: report from the working group.
Venous thromboembolism (VTE) is a major therapeutic issue in cancer patients. Advances in this field and heterogeneities in clinical practices prompted us to establish guidelines in the management of VTE in cancer patients according to the SOR (Standards, Options and Recommendations) methodology. A literature review of the studies published on this topic between 1999 and 2007 was performed. The guidelines were developed from the analysis of 38 out of 418 publications selected. They were peer-reviewed by 65 independent experts. The treatment of VTE in patients with cancer, including those with intracranial malignancies, should be based on low-molecular-weight heparins administered at therapeutic doses for at least 3 months. In the event of recurrent VTE, pulmonary embolism with hemodynamic failure or contra-indication to anticoagulant treatment, the indications and usages of vena cava filters and thrombolytic drugs should be the same as in non-cancer patients.
Farge
Dominique
D
Service de médecine interne et pathologie vasculaire, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris and INSERM U976, Paris VII University, France. publications@institutcancer.fr
Bosquet
Lise
L
Kassab-Chahmi
Diana
D
Mismetti
Patrick
P
Elalamy
Ismail
I
Meyer
Guy
G
Cajfinger
Francis
F
Desmurs-Clavel
Hélène
H
Elias
Antoine
A
Grange
Claire
C
Hocini
Hamid
H
Legal
Grégoire
G
Mahe
Isabelle
I
Quéré
Isabelle
I
Levesque
Hervé
H
Debourdeau
Philippe
P
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005602:France; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D054556:Venous Thromboembolism / Q000150:complications* / Q000188:drug therapy*; D014812:Vitamin K / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; D014812:Vitamin K; D006493:Heparin